Cross-sectional retrospective analysis of clinical characteristics of chronic hepatitis B patients with oral antiviral treatment in eastern China
-
Published:2021-01-13
Issue:1
Volume:18
Page:
-
ISSN:1743-422X
-
Container-title:Virology Journal
-
language:en
-
Short-container-title:Virol J
Author:
Gu Jueqing, Yu Guodong, Zhang Xiaoli, Zhang Shanyan, Cai Huan, Ye Chanyuan, Yang YidaORCID, Li Dezhou, Tong Zhaowei, Shen Huajiang, Chen Huazhong, Ding Feng, Lai Xijie, Liu Junyan, Xu Meiling, Wu Weiti
Abstract
Abstract
Background
In China, more than 20 million patients with chronic hepatitis B need antiviral treatment. Side effects of antiviral treatment such as renal complications can be problematic, particularly in an aging population.
Methods
The data were retrospectively extracted from the hospital medical charts of five centers in eastern China from January 1 to December 31, 2018.
Results
A total of 8309 patients with CHB was enrolled in this study. The median age of the patients was 46 years. The prevalence of diabetes mellitus, hypertension, and hepatic cirrhosis was respectively 3.49%, 4.42%, and 23.72%. The prevalence of these comorbidities increased with age (P < 0.001). Of the patients with CHB, 5332 had complete renal function results. Among them, patients with an estimated glomerular filtration rate of < 60 mL/min/1.73m2 accounted for 4.14%, and those with proteinuria for 8.33%. According to the definition of chronic kidney disease, the proportion of patients with chronic kidney disease was 11.37%. The prevalence of chronic kidney disease increased with age (P < 0.001). In a multivariate analysis, age group [odds ratio (OR) = 2.387], diabetes mellitus (OR = 1.486), hypertension (OR = 2.557), hepatic cirrhosis (OR = 1.295), and a history of exposure to adefovir dipivoxil (OR = 1.644) were significantly associated with CKD (P < 0.05). Among patients with CKD, 17.66% (107/606) had a history of lamivudine exposure, and 34.65% (210/606) had a history of nucleotide analogue exposure
Conclusion
The management of Chinese patients with CHB should take into consideration age, previous medication history, and renal impairment.
Funder
the Mega-Project of National Science and Technology for the 13th Five-Year Plan of China Chinese Foundation for Hepatitis Prevention and Control: TianQing Liver Diseases Research Fund Subject Shaoxing Civic Public Welfare Technology Application and Research Project Gilead Sciences
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Virology
Reference39 articles.
1. Razavi-Shearer D, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383–403. 2. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, et al. Reprint of: epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2013;31(Suppl 9):J21-28. 3. Yan YP, Su HX, Ji ZH, Shao ZJ, Pu ZS. Epidemiology of hepatitis B virus infection in China: current status and challenges. J Clin Transl Hepatol. 2014;2(1):15–22. 4. Xia GL, Liu CB, Cao HL, Bi SL, Zhan MY, Su CA, et al. Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D and E virus infections in China, 1992. Int Hepatol Commun. 1996;5:62–73. 5. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Wang F, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC, Wang Y. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009;27(47):6550–7.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|